A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day

Completed

Conditions studied: Arthritis Rheumatoid

In brief

It is hypothesized that patients prescribed tofacitinib 11 mg Modified Release (MR) formulation once daily (QD) will achieve similar benefit to those prescribed tofacitinib 5 mg twice a day (BID) dosage in real world use. This study will therefore seek to compare the effectiveness of the MR 11 mg QD regimen to the IR 5 mg BID regimen for the treatment of RA in a real-world registry of RA patients.

Key facts

Study ID

NCT04267380

Run by

Pfizer

People needed

298

Starts

2018-09-30

Expected to finish

2019-08-31

Last updated by the study team

2023-05-22

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All US Corrona RA Registry patients who initiated tofacitinib 5 mg twice a day (BID) or tofacitinib 11 mg once daily (QD) after it became available in February 2016
• Patients must have a follow-up visit at 6 months (+/- 3 months) after tofacitinib initiation. These 6 month visits are part of routine practice and is not associated with this protocol.
• Patients must have a valid clinical disease activity index (CDAI) at initiation and at 6-month follow-up visit

You may not qualify if…

• There are no exclusion criteria for this study.

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.